SOAM
CGON icon

SBI Okasan Asset Management’s CG Oncology CGON Stock Holding History

SBI Okasan Asset Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Buy
15,600
+3,500
+29% +$229K 0.04% 117
2026
Q1 		$774K Buy
12,100
+3,100
+34% +$176K 0.03% 145
2025
Q4 		$359K Buy
+9,000
New +$372K 0.02% 207

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SBI Okasan Asset Management's CGON Position: Q2 2026 in Review

SBI Okasan Asset Management increased its CG Oncology (CGON) stake by 29% in Q2 2026, buying an estimated $229K and bringing the position to 15,600 shares worth $1.15M. The position accounts for 0.04% of the portfolio, ranked #117.

SBI Okasan Asset Management first reported a position in CGON in Q4 2025 and has held it in 3 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • SBI Okasan Asset Management held 15,600 shares of CG Oncology worth $1.15M as of Q2 2026.
  • SBI Okasan Asset Management bought 3,500 CG Oncology shares in Q2 2026, an estimated $229K.
  • CG Oncology made up 0.04% of SBI Okasan Asset Management's portfolio in Q2 2026, its #117 holding.
  • SBI Okasan Asset Management first reported a position in CG Oncology in Q4 2025 and has held it in 3 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on SBI Okasan Asset Management's 13F filing for Q2 2026, filed 22 Jul 2026.